These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 34295338)

  • 1. Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.
    Pi YN; Qi WC; Xia BR; Lou G; Jin WL
    Front Immunol; 2021; 12():697083. PubMed ID: 34295338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review.
    Arshi A; Mahmoudi E; Raeisi F; Dehghan Tezerjani M; Bahramian E; Ahmed Y; Peng C
    Front Immunol; 2024; 15():1446937. PubMed ID: 39257589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA: a dazzling dancer in tumor immune microenvironment.
    Zhang Y; Liu Q; Liao Q
    J Exp Clin Cancer Res; 2020 Nov; 39(1):231. PubMed ID: 33148302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long noncoding RNAs in cancer-immunity cycle.
    Yu WD; Wang H; He QF; Xu Y; Wang XC
    J Cell Physiol; 2018 Sep; 233(9):6518-6523. PubMed ID: 29574911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long Non-coding RNAs: Regulators of the Activity of Myeloid-Derived Suppressor Cells.
    Leija Montoya G; González Ramírez J; Sandoval Basilio J; Serafín Higuera I; Isiordia Espinoza M; González González R; Serafín Higuera N
    Front Immunol; 2019; 10():1734. PubMed ID: 31404149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
    Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive Roles of Galectin-1 in the Tumor Microenvironment.
    Huang Y; Wang HC; Zhao J; Wu MH; Shih TC
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA loss in immune suppression in cancer.
    Hu Q; Egranov SD; Lin C; Yang L
    Pharmacol Ther; 2020 Sep; 213():107591. PubMed ID: 32473960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy.
    Eptaminitaki GC; Wolff N; Stellas D; Sifakis K; Baritaki S
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomes as mediators of immune regulation and immunotherapy in cancer.
    Kugeratski FG; Kalluri R
    FEBS J; 2021 Jan; 288(1):10-35. PubMed ID: 32910536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noncoding RNAs in Cancer Immunology.
    Li Q; Liu Q
    Adv Exp Med Biol; 2016; 927():243-64. PubMed ID: 27376738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining epigenetic and immune therapy to overcome cancer resistance.
    Gomez S; Tabernacki T; Kobyra J; Roberts P; Chiappinelli KB
    Semin Cancer Biol; 2020 Oct; 65():99-113. PubMed ID: 31877341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomes: Powerful weapon for cancer nano-immunoengineering.
    Pi YN; Xia BR; Jin MZ; Jin WL; Lou G
    Biochem Pharmacol; 2021 Apr; 186():114487. PubMed ID: 33647264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
    Nakamura K; Smyth MJ
    Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment.
    Susek KH; Karvouni M; Alici E; Lundqvist A
    Front Immunol; 2018; 9():2159. PubMed ID: 30319622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy.
    Srivastava A; Rathore S; Munshi A; Ramesh R
    AAPS J; 2021 Feb; 23(2):30. PubMed ID: 33586060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
    Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
    Front Immunol; 2021; 12():652160. PubMed ID: 33859645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
    Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C
    Front Immunol; 2021; 12():754196. PubMed ID: 35003065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Immune Microenvironment and Its Related miRNAs in Tumor Progression.
    Xing Y; Ruan G; Ni H; Qin H; Chen S; Gu X; Shang J; Zhou Y; Tao X; Zheng L
    Front Immunol; 2021; 12():624725. PubMed ID: 34084160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs and lncRNAs-A New Layer of Myeloid-Derived Suppressor Cells Regulation.
    Safarzadeh E; Asadzadeh Z; Safaei S; Hatefi A; Derakhshani A; Giovannelli F; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2020; 11():572323. PubMed ID: 33133086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.